External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology SABCS 2024
Roche and Genentech at

SABCS 2024

December 10 - December 13
San Antonio, USA / Virtual (Hybrid)
sabcs.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
11:30 PM
Duration 29mins San Antonio, USA
First-line inavolisib/placebo + palbociclib + fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer who relapsed during/within 12 months of adjuvant endocrine therapy completion: long-term safety from INAVO120
Saura C, Turner NC, Jhaveri K, Im SA, Loibl S, Schmid P, Loi S, Juric D, Tryfonopoulos D, Bedard P, Yap YS, Villanueva V, Gokmen E, Bondarenko I, Wang X, Papazisis K, Thanopoulou E, Shankar N, Lim S, Jin Y, Song C, Stout T, Kalinsky K
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 29mins San Antonio, USA
Real-world data on cyclin-dependent kinase 4/6 inhibitor switching in patients with first-line hormone receptor-positive, HER2-negative metastatic breast cancer
Chen L, Secrest M, Lopez-Valverde V, Perez-Moreno P, Kalinsky K, Zambelli A
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
01:00 PM
Duration 30mins San Antonio, USA
ZN-1041, a potential best-in-class BBB Penetrable HER2 Inhibitor, has high antitumor activity in patients with Breast Cancer with CNS Metastases
Ma F, Li Y, Yao H, Wang J, Ouyang Q, Cheng J, Li X, Dinglin X-X, Jin G, Zhou H, Wang X, Teng Y, Wang Y, Dang Q, Yang J, Xiong H-H, Zhao W, Cai L, Fu T, Zhu D
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
11:30 PM
Duration 29mins San Antonio, USA
pionERA Breast Cancer (BC): Phase III study of first-line (1L) giredestrant vs. fulvestrant, both combined with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i), in patients (pts) with estrogen receptor-positive (ER+), HER2- locally advanced/metastatic BC (LA/mBC) with resistance to prior adjuvant endocrine therapy (ET)
Kalinsky K, Jeselsohn R, Bellet M, Fasching PA, Gomez-Abuin G, Jung KH, Lavalle S, Valverde VL, Lu YS, Schwab R, Turner NC, Breton VL, Zambelli A, Andre F
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 29mins San Antonio, USA
Preliminary safety analysis of the inavolisib + fulvestrant + ribociclib/abemaciclib arms in MORPHEUS-pan BC: a phase Ib/II study evaluating the efficacy and safety of multiple treatment combinations in patients with metastatic or locally advanced breast cancer
Sonnenblick A, Loi S, Martin H, Oliveira M, Soong J, Young F, Cahuzac C, Shemesh C, Song C, Kallapur K, Schwab R, Gal-Yam E
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 29mins San Antonio, USA
Real-world observational study of patients with endocrine-resistant, hormone receptor+, HER2– metastatic breast cancer in the first-line setting: Patient characteristics, PIK3CA mutation prevalence, treatments, and clinical outcomes
Dhillon P, Lambert P, Thanopoulou E, Kalinsky K
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
06:30 PM
Duration 29mins San Antonio, USA
DEMETHER: A single-arm phase II trial to evaluate the efficacy and safety of subcutaneous fixed-dose combination of pertuzumab and trastuzumab maintenance after induction treatment with trastuzumab deruxtecan (T-DXd) for previously untreated human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer (ABC)
Cortés J, Garcia Mosquera JJ, Antonarelli G, Gennari A, Barrios C, Curigliano G, Rugo H, Gligorov J, Harbeck N, Tolaney S, Gradishar WJ, Schmid P, Gion M, Zhan RR, Szostak E, Gonzalez-Alonso P, Verbeni M, Parez-Garcia JM, Llombart-Cussac A
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
11:30 PM
Duration 29mins San Antonio, USA
The global failure of mammography screening accessibility - a systematic literature review
Barrios C, Paluch-Shimon S, Muella E, Neeser K, Arnold M, Napalkov P, Azambuja E
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.